Last reviewed · How we verify
TR-701 FA single infusion
At a glance
| Generic name | TR-701 FA single infusion |
|---|---|
| Also known as | Tedizolid |
| Sponsor | Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of Oral and Intravenous (IV) Tedizolid Phosphate in Hospitalized Participants, Ages 2 to <12 Years, With Confirmed or Suspected Bacterial Infection (MK-1986-013) (PHASE1)
- Pharmacokinetic (PK) Study of Oral and IV TR-701 FA in Adolescent Patients (PHASE1)
- Ascending Dose Pharmacokinetic (PK) and Absolute Bioavailability (BA) (PHASE1)
- A Pharmacokinetics and Safety Study in Subjects With Renal Impairment (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: